AKERS BIOSCIENCES, INC. (LON:AKR) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.
On December 19, 2016, Akers Biosciences, Inc. (the Company) held
its 2016 annual meeting of stockholders (the Annual Meeting).
Greater than 33.34% of the shares of common stock outstanding and
entitled to vote at the Annual Meeting were present in person or
by proxy thereby constituting a quorum.
The matters that were voted upon at the Annual Meeting, and the
number of votes cast for or against/withheld, as well as the
number of abstentions, as to such matters, where applicable, are
set forth in the table below. With respect to the election of
Raymond F. Akers, Jr., Ph.D, Thomas Knox, Brandon Knox, Robert E.
Andrews, and Raza Bokhari as directors to each serve a one-year
term on the Board of Directors of the Company (the Board) and
until each of their successors is elected and qualified, each
nominee received the number of votes set forth opposite his name.
| Number of Votes | ||||||||||||
| Votes For | Votes Against/Withheld | Abstentions | ||||||||||
| Election of Raymond F. Akers, Jr. Ph.D | 1,114,807 | 32,768 | ||||||||||
| Election of Thomas Knox | 1,035,180 | 112,113 | ||||||||||
| Election of Brandon Knox | 993,380 | 153,913 | ||||||||||
| Election of Robert E. Andrews | 1,035,295 | 111,998 | ||||||||||
| Election of Raza Bokhari |
1,007,980 |
139,313 | ||||||||||
|
Ratification of Morison Cogen LLP, the Companys independent registered public accountant, to audit the Companys consolidated financial statements for 2016 |
1,928,133 | 349,744 | 2,000 | |||||||||
|
Non-binding advisory vote on the Companys Executive Compensation |
1,043,284 | 76,041 | 27,792 | |||||||||
On the basis of the above votes, (i) Raymond F. Akers, Jr., Ph.D,
Thomas Knox, Brandon Knox, Robert E. Andrews, and Raza Bokhari
were elected as members of the Board and (ii) the proposal to
ratify the selection of Morison Cogen LLP, as the Companys
independent registered public accountant to audit its
consolidated financial statements for 2016 was adopted.
The stockholders also voted a sufficient number of non-binding
advisory votes to approve the Companys executive compensation.
About AKERS BIOSCIENCES, INC. (LON:AKR)
Akers Biosciences, Inc. develops, manufactures and supplies point-of-care screening and testing products designed to bring health-related information to the patient or clinician. The Company’s product offerings and pipeline products focus on delivering diagnostic assistance in a range of healthcare fields/specialties, including cardiology/emergency medicine, metabolism/nutrition, diabetes, respiratory diseases and infectious diseases detection, as well as for on and off-the-job alcohol safety initiatives. The Company’s primary focus is the development and sale of disposable diagnostic testing devices that can be performed in minutes, to facilitate time sensitive therapeutic decisions. The Company’s main products include a disposable breathalyzer test that measures the blood alcohol content of the user, a rapid test detecting the antibody causing an allergic reaction to Heparin and a disposable breathalyzer test that measures Free Radical activity in the human body. AKERS BIOSCIENCES, INC. (LON:AKR) Recent Trading Information
AKERS BIOSCIENCES, INC. (LON:AKR) closed its last trading session down -17.50 at 145.00 with 0 shares trading hands.
